Evidence map›Paper›PMID 32274629›Full record

ArticleJournal of neuro-oncology2020

Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma.

Brittany L Voth, Panayiotis E Pelargos, Natalie E Barnette, Nikhilesh S Bhatt, Cheng Hao Jacky Chen, Carlito Lagman, Lawrance K Chung, Thien Nguyen, John P Sheppard, Prasanth Romiyo and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024
    Review
  2. Article
  3. Review
  4. International journal of molecular sciences · 2022
    Article
  5. Review
  6. Article
  7. Are the oxidative stress levels in the tumor center and tumor boundary different from those in healthy tissue?European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Brittany L VothDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Panayiotis E PelargosDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Natalie E BarnetteDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Nikhilesh S BhattDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Cheng Hao Jacky ChenDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Carlito LagmanDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Lawrance K ChungDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Thien NguyenDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
John P SheppardDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Prasanth RomiyoDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Sergey MareninovDepartments of Biological Chemistry, Jonsson Comprehensive Cancer Center, University of California, 300 Stein Plaza, Suite 562, 5th Floor Wasserman Building, Los Angeles, CA, 90095-6901, USA.
Valerie A KickhoeferDepartments of Biological Chemistry, Jonsson Comprehensive Cancer Center, University of California, 300 Stein Plaza, Suite 562, 5th Floor Wasserman Building, Los Angeles, CA, 90095-6901, USA.
William H YongDepartments of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Leonard H RomeDepartments of Neurosurgery, University of California, Los Angeles, CA, USA.
Isaac YangDepartments of Neurosurgery, University of California, Los Angeles, CA, USA. iyang@mednet.ucla.edu.
University of California, Los Angeles · USUCLA Jonsson Comprehensive Cancer Center

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlioblastoma (GBM) is the most common and malignant primary adult brain tumor. Current care includes surgical resection, radiation, and chemotherapy. Recent clinical trials for GBM have demonstrated extended survival using interventions such as tumor vaccines or tumor-treating fields. However, prognosis generally remains poor, with expected survival of 20 months after randomization. Chemokine-based immunotherapy utilizing CCL21 locally recruits lymphocytes and dendritic cells to enhance host antitumor response. Here, we report a preliminary study utilizing CPZ-vault nanoparticles as a vehicle to package, protect, and steadily deliver therapy to optimize CCL21 therapy in a murine flank model of GBM.

methodsGL261 cells were subcutaneously injected into the left flank of eight-week-old female C57BL/6 mice. Mice were treated with intratumoral injections of either: (1) CCL21-packaged vault nanoparticles (CPZ-CCL21), (2) free recombinant CCL21 chemokine empty vault nanoparticles, (3) empty vault nanoparticles, or 4) PBS.

resultsThe results of this study showed that CCL21-packaged vault nanoparticle injections can decrease the tumor volume in vivo. Additionally, this study showed mice injected with CCL21-packaged vault nanoparticle had the smallest average tumor volume and remained the only treatment group with a negative percent change in tumor volume.

conclusionsThis preliminary study establishes vault nanoparticles as a feasible vehicle to increase drug delivery and immune response in a flank murine model of GBM. Future animal studies involving an intracranial orthotopic tumor model are required to fully evaluate the potential for CCL21-packaged vault nanoparticles as a strategy to bypass the blood brain barrier, enhance intracranial immune activity, and improve intracranial tumor control and survival.

Indexed as

AnimalsBrain NeoplasmsCell Line, TumorChemokine CCL21Drug Delivery SystemsFemaleGlioblastomaImmunotherapyMice, Inbred C57BLNanoparticlesChemokine CCL21CancerCCL21GlioblastomaImmunotherapyNanoparticlesVaults

Identifiers

PMID32274629
OpenAlexW3015530303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.